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Abstract: The development of cancer immunotherapy in the last decade has followed a vertiginous
rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1
and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However,
approximately only a third of the patients benefit from ICI therapies. Many efforts have been made
for the identification of biomarkers allowing patient stratification into potential responders and
progressors before the start of ICI therapies or for monitoring responses during treatment. While
much attention is centered on biomarkers from the tumor microenvironment, in many cases biopsies
are not available. The identification of systemic immune cell subsets that correlate with responses
could provide promising biomarkers. Some of them have been reported to influence the response
to ICI therapies, such as proliferation and activation status of CD8 and CD4 T cells, the expression
of immune checkpoints in peripheral blood cells and the relative numbers of immunosuppressive
cells such as regulatory T cells and myeloid-derived suppressor cells. In addition, the profile of
soluble factors in plasma samples could be associated to response or tumor progression. Here we will
review the cellular subsets associated to response or progression in different studies and discuss their
accuracy in diagnosis.
Keywords: immunotherapy; immune checkpoint inhibitors; systemic blood subsets; CD4+;
CD8+; MDSCs
1. Introduction
The roots of cancer immunology can be dated back to the nineteenth century. However, it
is in the past few decades when immunotherapies have emerged as realistic options for cancer
treatment. One of the pillars of this radical change has been the encouraging results obtained in
several clinical trials with immune checkpoint inhibitors (ICI) such as anti-CTLA4, anti-PD-1 and
anti-PD-L1 antibodies. Nowadays, the anti-CTLA4 ipilimumab (Bristol-Meyers Squibb), the anti-PD-1
nivolumab (Bristol-Meyers Squibb), pembrolizumab (Merck), and the anti-PD-L1 atezolizumab (Roche)
are approved for the treatment of numerous cancers (e.g., melanoma, NSCLC, RCC).
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However, despite of durable clinical benefits in many patients, a significant number of patients
are still refractory ICI therapies. Hence, the early identification of potential responders and progressors
would be a very important step forward. This is of special importance, as some of the treated patients
develop hyperprogressive disease. Ideal biomarkers would enable the stratification of patients before
the start of immunotherapies, and also the real-time monitoring of response for the duration of
the treatments.
One of the most extensively used biomarkers is tumor expression of PD-L1. There is ample evidence
that PD-L1 overexpression correlates with immune evasion of immunogenic tumors. Therefore, the
percentage of PD-L1 expression in tumor biopsies is used as a stratification factor for pembrolizumab
administration in non-small cell lung cancer (NSCLC) or melanoma [1–4]. However, the usefulness
of PD-L1 expression as a biomarker is still under debate, as patients with PD-L1-negative cancer
cells can also respond to ICI therapies. Moreover, many PD-L1 detection protocols are not currently
standardized [5]. For example, PD-L1 expression in myeloid cells may also play a role in response or
resistance for the treatment of PD-L1 negative tumors, even when anti-PD-L1 antibody (atezolizumab)
was the treatment of choice [6]. In these cases, the relative abundance of PD-L1+ CD11b+ myeloid cells
in systemic blood correlated with clinical responses in lung cancer. These results indicated that PD-L1
expression in systemic immune cell populations can be a potential predictive biomarker of responses
to PD-L1/PD-1 blockade therapy.
The tumor mutational burden (TMB) has recently gained popularity as a predictive biomarker
associated with ICI responses. TMB provides a quantification of the number of mutations per megabase
of genomic DNA within the tumor encoding genome. Indeed, there is a high mutational heterogeneity
in different tumors types [7,8]. Patients with high TMB achieved a higher overall response rate (ORR)
and a higher median progression-free survival (PFS), and therefore a better response to immunotherapy
in NSCLC [9]. In addition to TMB, cancer DNA mismatch repair (MMR) gene mutations are quite
relevant, and they are used as clinically applicable biomarkers [10,11]. It has been reported that MMR
predicted clinical benefit of pembrolizumab in colon cancer [12]. Thus, tumor DNA-based sequencing
approaches could be a key approach for the identification of patients who might respond to therapy.
The identification of biomarkers in peripheral blood that may accurately correlate with response
to ICI therapies could provide a simple non-invasive method for patient selection, or even for treatment
monitoring. The quantification of some of the biomarkers mentioned above requires tumor samples
and biopsies that are not always available from every patient, or lacking at different time points during
therapy. Biomarkers available before the start of ICI therapies can come from multiple sample types,
and these can be useful for decision-making on specific treatment options. However, blood biomarkers
can be a better option during the follow-up of patients along the duration of therapies. Blood samples
provide two different data types: (1) Soluble biomarkers in plasma or serum, and (2) the composition
of immune cell populations in whole blood or peripheral blood mononuclear cell (PBMC) fraction.
Quantification of soluble biomarkers has been reviewed elsewhere [13,14]. In this review we will focus
on immune cell populations in peripheral blood as predictors of responses to ICI therapies, and the
immune-related mechanisms that ICI therapies activate through these cells.
2. Total Cell Counts and Ratios
Some of the immune correlates classically used to predict response or progression include
changes in the lymphocyte/neutrophil compartment and blood cell counts with prognostic
value [15–17]. For example, an absolute lymphocyte count (ALC) ≥ 1000/µL and neutrophil
count (ANC) <4000/µL during treatment correlates with increased overall survival in melanoma
patients treated with nivolumab [18,19]. It is not surprising that classical prognostic variables such as
neutrophil-to-lymphocyte ratio (NLR) or serum lactate dehydrogenase (LDH) have been evaluated as
potential predictors of response or resistance. Hence, high pretreatment NLR ratios (>2.2) and high
LDH correlate with progression in nivolumab-treated patients with advanced NSCLC [20]. This is in
agreement with other studies that utilize NLR as a biomarker in oncology [18,21,22].
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3. CD8 T Cells
Cytotoxic CD8 T cells (cytotoxic T lymphocytes, CTLs) are considered the main effectors
of anti-tumor immune responses. CTLs differentiate from naïve CD8 T cells activated by
antigen-presenting cells (APCs) in lymphoid organs. In the context of anti-tumor immunity, cytotoxic
T cells recognize tumor-derived peptides complexed to MHC molecules through binding of their T cell
receptor (TCR) by interacting with APCs. Other sources of CTLs derive from activation of circulating
central and effector memory T cells. This mechanism allows the rapid activation of a faster immune
response after re-encounter with tumor antigens. After activation of naïve T cells or after differentiation
from memory T cells, CTLs proliferate and migrate to the tumor, where these exert cytotoxic activities
over cancer cells using different mechanisms. It is in the tumor microenvironment (TME), however,
where CTLs can be inhibited by inhibitory signals delivered from cancer and immunosuppressive cells.
The balance between CTL cytotoxicity and the immunomodulatory action of the TME leads to
three possible scenarios: Tumor suppression, equilibrium, or tumor evasion. The importance of these
interactions in the TME is exemplified by the expression of immune checkpoint inhibitor ligands such
as PD-L1. And a high infiltration of T cells in the TME is on the other hand and in general terms a
good indicative of ICI efficacy.
Considering that T cell activation results in strong proliferation, it is not surprising that the number
of total lymphocytes (assessed by parameters as absolute lymphocyte counts, or ALC) or specific T cell
subsets (CD8 or CD4) might be considered good predictors of outcomes after ICI therapies. In a study
with 82 melanoma patients treated with ipilimumab, Martens et al. found that an early increase in
ALC 2 to 8 weeks after the start of treatments, followed by an increase in the relative percentages of
CD4 and CD8 T cells (8-14 weeks after starting with treatment) correlated with improved survival [23].
Furthermore, the expression of proliferation markers such as Ki67 can also provide a more exact
quantification of proliferation. A low baseline percentage of Ki67+ EOMES+ CD8 T cells in blood was
associated with a higher possibility of relapse in melanoma patients treated with ipilimumab [24].
EOMES is a transcription factor that regulates expression of IFN-γ, granzyme B and perforin, being
also a marker for T cell activation. The authors of this study showed that patients stratified according
to a higher baseline proportion of Ki67+ EOMES+ CD8 T cells had an improved relapse-free survival.
The expression of immune checkpoints in peripheral blood T cells has also been studied as a
stratifying parameter as well, alone or in combination with proliferation markers. Jacquelot et al.
recruited 190 metastatic melanoma patients treated with ipilimumab from 8 cohorts, and showed
that high PD-L1 expression in CD8 T cells was associated with worse OS [25]. Kamphorst et al. also
observed an increase of circulating HLA-DR+ CD38+ Ki67+ PD-1+ CD8 T cells in NSCLC patients
following anti-PD-1 treatment which correlated with good responses. CD8 T cells in patients with a
two-fold increase in the Ki67+ PD-1+ subset showed also increased CD28 expression, which implies
that CD28+ CD8 T cells play a major role in objective responses to ICI therapies [26]. Another study
expanded this observation by quantifying the ratio of Ki67+ PD1+ CD8 T cells after pembrolizumab
treatment to baseline tumor burden as a good indicator of prolonged PFS in melanoma patients [27].
The distribution of memory versus non-memory cells in CD8 T cell populations has been associated
to anti-CTLA4 therapy responses to but not to anti-PD-1 therapy in melanoma patients. High baseline
percentages of effector memory CD8 T cells correlated with longer OS and with enhanced clinical
responses [28–30]. However, a study in NSCLC patients receiving nivolumab uncovered that patients
with a high central memory/effector CD8 T cell ratio had longer PFS [31].
4. CD4 T Cells
The recent past years have witnessed the surge of CD4 T cells into the scene of tumor immunity.
Naïve CD4 T cells recognize tumor antigens similarly to CD8 T cells, but differing in the mode of
presentation by APCs (MHC-II versus MHC-I). After activation, CD4 T cells proliferate and differentiate
into helper subsets (Th1, Th2, Th9, and Th17) or regulatory T (Treg) cells depending on the cytokines
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and other factors present during their differentiation. Some of these CD4 T cells possess anti-tumor
activities, while others exert immunosuppressive activities mainly by regulating the CD8 response.
Overall, most studies have broadly found equivalent changes in CD8 and CD4 T cells during
anti-tumor responses. Thus, strong CD4 proliferation has been associated with good prognosis in
agreement with CD8 responses [23,24]. In contrast, high expression of immune checkpoints both in
CD4 and CD8 T cells correlates with resistance to therapy [25].
According to the identification of specific CD4 T cell subsets, a study including 46 metastatic
melanoma patients treated with nivolumab showed that increase in Th9 frequency in responders,
which also correlated with higher levels of serum TGFβ and higher percentages of IL4-producing
CD4 T cells [32]. The authors of this study proposed that Th9 cells possessed anti-tumor capacities by
regulating the expression of cytotoxic molecules by CTLs.
We have been interested for several years in PD-L1/PD-1 signaling mechanisms in the context
of antitumor immunity. We carried out a recent translational project quantifying the relative
percentages in peripheral blood of CD4 and CD8 T cell differentiation subsets in NSCLC patients
treated with anti-PD-1/PD-L1 immunotherapies [33]. T cells can be classified according to CD27
and CD28 expression profiles into poorly differentiated (CD27+CD28+), intermediately differentiated
(CD27-CD28+), and highly differentiated (CD27-CD28-) subsets. Patients were stratified into two
groups by an approximately baseline cut-off value of 40% CD27- CD28- highly differentiated CD4 T
cells. Interestingly, objective responders had percentages above this cutoff value, while patients with a
percentage below this cut-off were refractory to the treatment. Hence, patients with a high percentage
of highly differentiated CD4 T cells showed longer PFS and OS. Interestingly, no clear correlation was
found between the relative percentages of baseline CD8 T subsets with the efficacy of immunotherapies.
Moreover, highly differentiated CD4 T cells corresponded to both central and effector memory cells
but not to senescent or exhausted cells. Our results were also in very close agreement by a detailed
and complete study carried out by Kagamu et al. These authors used mass cytometry and found that
NSCLC patients responding to nivolumab had a significantly higher percentage of CD62Llow CD4
T cells than non-responders at baseline [34]. Interestingly, these T cells were also double negative
in CD27 and CD28, and corresponded to memory subsets. Importantly, the cut-off values from
our study and their study were found to be nearly the same, strongly suggesting that CD4 T cell
quantification in peripheral blood is a predictive biomarker with clinical value. Moreover, in a recent
study including NSCLC and RCC patients treated with nivolumab and pembrolizumab, authors also
highlighted the relevance of central memory CD4 T cells for tumor immunity. The baseline percentage
of central memory CD4 T cells was higher in responder patients or patients with stable disease than
in patients with progressive disease [35]. Taken together, the data from these independent studies
highlight the relevance of the CD4 systemic immunity for anti-tumor immunity and clinical responses
to ICI therapies.
Tregs constitute a special immunosuppressive subset that can be differentiated in the thymus
(natural Tregs) or from naïve CD4 T cells (inducible Tregs). Tregs promote immunosuppression
and tolerance once infiltrated into the TME. Accordingly, a decrease in peripheral blood Tregs
after ipilimumab treatment in metastatic melanoma patients was associated to disease control and
OS [36], while the baseline percentage of CD25+ FoxP3+ CD4 T cells in NSCLC patients treated with
nivolumab was higher in non-responders [34]. These results overall suggest that a decrease of this
immunosuppressive population contributes to the efficacy of ICI therapies. However, another study
found that baseline percentages ≥ 1.5% of CD4+ CD25+ FoxP3+ Tregs were associated with good
prognosis in patients receiving ipilimumab [37]. In agreement with this latter study, Tarhini et al.
showed that an increase in Treg percentage in advanced melanoma patients treated with neoadjuvant
ipilimumab correlated with prolonged PFS [38]. A potential explanation for these discrepancies
may lay on the varying suppressive capacities of Tregs following ICI therapy. For example, Woods
et al. found that metastatic melanoma patients responding to nivolumab showed an increase in
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circulating Tregs, but these cells had increased phosphorylated STAT3 which correlated with reduced
immunosuppressive activity [39].
5. NK Cells
Natural killer (NK) cells group several types of lymphocytes with an innate capacity to recognize
and eliminate tumor cells, without the need of a previous immunization to become activated. There
are few studies on circulating NK cells as potential biomarkers of responses to ICI therapy, probably
because their activities are mainly exerted within the TME [40].
In a study using CyTOF mass cytometry, Subrahmanyam et al. found that melanoma patients
responding to anti-PD-1 antibodies had a baseline higher expression of CD69 and MIP-1β in NK
cells stimulated with PMA and ionomycin [28]. This study indicates a potential role for differentially
activated NK cells in the response to ICI therapy, as unstimulated cells showed comparable CD69 and
MIP- between responders and non-responders.
6. MDSCs
Myeloid-derived suppressor cells (MDSCs) constitute a heterogeneous group of myeloid cells
with immunosuppressive activities that expand particularly during in chronic inflammatory conditions
such as cancer [41,42]. MDSCs are usually divided in two major subsets: Monocytic (mMDSCs) and
granulocytic MDSCs (gMDSCs or polymorphonuclear (PMN)-MDSCs). The increase in circulating
MDSCs is a consequence of an altered myelopoiesis and generally correlates with MDSC infiltration in
the TME. Many reports have shown the relationship between the number of MDSCs and treatment
outcome in cancer patients. Indeed, the percentage of peripheral blood MDSCs has some prognostic
value for ICI therapy.
Sade-Feldman et al. showed that the baseline percentage of circulating total CD33+ CD11b+ HLA-
DR- MDSCs in melanoma patients treated with ipilimumab inversely correlated with response and
OS [43]. However, the authors did not discriminate between mMDSCs and gMDSCs. Furthermore,
several studies have found that melanoma patients with lower baseline numbers of circulating
mMDSCs had a higher chance of responding to ipilimumab treatment with improved OS [37,44–46].
This correlation is not restricted to ICI immunotherapies, as it was also found in castration-resistant
prostate cancer patients treated with the cancer vaccine GVAX plus ipilimumab [47]. In addition, other
studies in melanoma patients showed the relevance of changes in mMDSC relative numbers following
treatment with ipilimumab. Coaña et al. showed that patients with clinical benefit had a significant
reduction in mMDSC percentages right after the first dose of ipilimumab, even though no differences
were found in baseline percentages between responders and non-responders [48]. This study is in
agreement with others demonstrating that patients with a decrease in mMDSCs after the first doses of
ipilimumab had increased survival [38,49]. Interestingly, Kitano et al. showed that the percentage of
mMDSCs was inversely correlated with increase CD8 T cell absolute numbers following ipilimumab
treatment [50]. Taken together, these studies suggest that low baseline percentages of peripheral
mMDSCs before starting ICI therapy, or their decrease after the start of therapy are indicators of
positive outcomes.
7. Monocytes and Macrophages
Tumor-associated macrophages (TAMs) are classically one of the main immunosuppressive
myeloid cells infiltrating the TME. TAMs can directly derive within the TME from resident macrophages
through polarization towards a M2-like phenotype or from monocytes and mMDSCs through
differentiation. However, most TAMs arise from the circulating pool of classical “uncommitted”
monocytes. It has to be taken into account that tumor infiltration with monocyte-derived M1-polarized
macrophages does have anti-tumor activities in the TME. In blood, monocytes are classified according
to CD14 and CD16 expression profiles. CD14highCD16- correspond to classical monocytes which are
recruited to tissues following inflammation or damage; CD14highCD16dim consists of intermediate
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monocytes; and CD14lowCD16high correspond to non-classical monocytes with surveillance functions.
Nevertheless, the abundances of distinct circulating monocytes are not reflecting what takes place in
the tissue, and there are only a few indications about changes in blood monocytes associated with
clinical outcome after ICI therapy.
A study in melanoma patients treated with ipilimumab uncovered that responders displayed
higher baseline percentages of non-classical monocytes than non-responders [51]. Moreover, an
increased frequency of baseline CD14+ CD16- HLA- DRhigh classical monocytes as quantified by
CyTOF correlated with enhanced PFS and OS in melanoma patients treated with anti-PD-1 therapy [17].
Further research will be needed to understand the participation of each subset of circulating monocytes
in tumor immunity, and their utility as predictors of therapeutic efficacy.
8. Immune Cell Populations in Patients with Hyperprogression after ICI Therapy
A series of independent research teams have reported a deleterious effect of PD-1/PD-L1 blockade
immunotherapy, termed hyperprogressive disease (HPD). HPD is characterized by an acceleration of
tumor growth kinetics resulting in fast progression associated to quick clinical deterioration, although
the specific clinical criteria for its definition are still controversial [52–54]. The mechanisms of HPD
are largely unknown, although two recent studies have proposed as possible causes the binding
of anti-PD-1 IgG4 with the Fc receptor in macrophages, or proliferation of tumor-infiltrating PD-1
expressing Tregs [55,56]. The identification of reliable biomarkers for detection of patients with a high
probability of developing HPD after ICI therapies is a matter of special importance.
Several clinical factors have been linked to HPD, including age≥ 65 years [52], liver metastases [54]
or locoregional relapse in head and neck squamous cell cancer (HNSCC) [53] among others. According
to the identification of predictive biomarkers in peripheral blood, a retrospective study that included
62 advanced gastric cancer (AGC) patients treated with nivolumab found an association of several
biomarkers to HPD. Levels of serum C-reactive protein (CRP) (median 4.0 versus 0.50 mg/dL, p = 0.006),
lactate dehydrogenase (LDH) (median 396.0 versus 179.5 U/L, p = 0.006) or absolute neutrophil count
(ANC) (median 4490 versus 2720/µL, p = 0.002) were significantly higher in patients that ended
up developing HPD. Furthermore, ANC and CRP remained elevated 4 weeks after the start of
immunotherapy with nivolumab in patients with HPD (7740 versus 4490/µL and 8.3 versus 4.0 mg/dL
respectively) [57]. No prospective studies of any biomarker associated to HPD have been published
so far with the exception of one [58]. In the study by Arasanz et al., peripheral blood immune
cell populations were quantified by flow cytometry in patients with advanced NSCLC treated with
immune-checkpoint inhibitors (ICI) as second or further lines of therapy. A sharp expansion of highly
differentiated CD4 T cells between the first and the second cycle of immunotherapy was observed
in HPD patients. An increase of this population superior to 30% identified HPD patients with a 82%
specificity and 70% sensitivity. Tumor growth ratio (TGR), as defined by Champiat et al. [54] was
significantly higher for HPD patients compared to non-HPD progressors (2.67 versus 1.03, p = 0.0126).
By multivariate analysis, only the expansion of highly differentiated CD4 T cells and PD-L1 tumor
expression higher than 5% were the only independent factors associated with HPD.
Finally, a recent meta-analysis that included 9 retrospective studies has been published. This
study confirmed the prognostic value of elevated serum LDH above the upper limit of normal (ULN),
with an odds ratio (OR) of 1.89 (95% CI 1.34 to 2.57, p = 0.043), but without finding any significant
value for the other peripheral blood variables under study [59].
9. Future Perspectives
We have reviewed here the current knowledge on the applicability of quantification of peripheral
blood immune cell populations as biomarkers to assess the efficacy of ICI therapies. Nevertheless,
cancer treatment is right now a continuously-changing field, and especially after the development
of clinically effective immunotherapies. The approval of novel antibodies directed towards immune
checkpoints other than PD-L1, PD-1, or LAG-3 together with the inclusion of combination therapies, is
prioritizing the search for biomarkers of response to immunotherapies.
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The improvement of well-established techniques such as flow cytometry, and the clinical
application of novel high throughput technologies such as mass cytometry-CYTOF is allowing
the identification and quantification of multiple cell subsets from small sample quantities. Accordingly,
early biomarkers based on crude quantification of ALC and total CD4/CD8 T cells have moved towards
the quantification of highly specific cell subsets. For example, highly-differentiated memory T cell
subsets, proliferating Ki67+ PD1+ CD8 T cells or CD14+ CD16- HLA-DRhigh classical monocytes. More
sophisticated technical approaches coupled to highly detailed multidimensional statistical analyses
will expand our knowledge on the participation of peripheral blood cell subsets in the efficacy of
cancer therapies. Although the introduction of some of these techniques in clinical practice can be
complicated right now, perhaps our efforts should be driven towards the design of simpler analyses
once the specific targets have been identified.
The expression of immune checkpoints in peripheral immune cells provides another level of
information, although their quantification could result in a double-edged sword. Increased levels of
immune checkpoints may identify T cells that could be re-activated with the use of the appropriate
inhibitors. However, the up-regulation of alternative inhibitory molecules can indeed counteract the
action of a particular inhibitor. In NSCLC patients under anti-PD-1/anti-PD-L1 immunotherapy that
we have analyzed, most non-responders had T cells that simultaneous co-expressed PD-1 and LAG-3.
Indeed, co-blockade with a combination of anti-PD-1 and anti-LAG-3 antibodies was sufficient to
increase T cell activation from non-responder patients [33]. Fine mapping of the expression profiles of
immune checkpoints in peripheral T cells could be indicative of the particular inhibitor combination to
be used in these patients, especially when a plethora of other ICI are currently under study in different
clinical trials.
The expression of ligands for immune checkpoints in peripheral blood immune cells can also
be considered to evaluate responses to ICI therapies. Jacquelot et al. found that PD-L1 expression
in circulating CD8 T cells was associated with good prognosis in melanoma patients treated with
ipilimumab [25] Although the expression of PD-L1 is mainly quantified in tumor cells or in infiltrating
immune cells within the TME, it can also be highly expressed by peripheral blood myeloid cells.
In a clinical case study, two tumor PD-L1-negative NSCLC patients with similar clinical history
exhibited a remarkably different response to atezolizumab. The responder patients showed a high
baseline percentage of PD-L1-expressing myeloid cells [6]. This observation was corroborated in an
exploratory follow-up study of 31 patients with advanced NSCLC, suggesting that quantification of
systemic PD-L1+ myeloid cell subsets could complement other biomarkers for patient stratification,
independently of PD-L1 expression in tumor biopsies.
An emerging and promising candidate as a biomarker for immunotherapies is the quantification
of the TCR repertoire and its changes in peripheral T cells before and during therapy. It was speculated
that having a high TCR clonal diversity could correlate with higher probabilities to establish efficacious
anti-tumor immune responses. Consequently, several studies have indeed associated a better response
to a more diverse TCR repertoire in peripheral T cells [60–63].
10. Concluding Remarks
The search for specific biomarkers that predict the outcome of cancer patients after ICI therapy
is still ongoing. Quantification of baseline immune cell populations in peripheral blood or during
treatments is supporting the hypothesis that active CD4 and CD8 T cell proliferation and activation,
high frequency of memory cells and low numbers of immunosuppresive cells are indicative of good
prognosis (Table 1). These results could be added to other clinical data, including analyses of tumor
biopsies if available for biomarkers such as TMB or PD-L1 expression (which is so far the only biomarker
used in clinical settings).
However, it is intriguing that we can find many apparently contradictory reports when comparing
different studies. For example, studies that have found changes in CD8-based immunity sometimes do
not simultaneously identify changes in CD4-dependent systemic immunity. A possible explanation
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could be the specific set of markers used by different studies and the variability in ICI treatments
and patient cohorts. We propose the derivation of a sequential algorithm integrating the different
biomarkers, taking into account our current understanding as shown in Figure 1.
Table 1. Levels of specific peripheral immune cells correlated with clinical outcome of cancer patients
under ICI therapy.
Cell Type Correlation with Clinical Benefit or Prolonged OS/PFS References
CD8 T cells
High proliferation [24,37]
High expression of immune checkpoints (PD-1) [16,27]
High memory CD8 T cell numbers [28–30]
CD4T cells
Increased proliferation [24,37]
High frequency of Th9 cells [32]
High percentage of highly differentiated (CD27-CD28-) CD4 T cells [33]
High percentage of memory CD4 T cells [33–35]
Low Treg numbers or high numbers with reduced
immunosuppressive activity [23,36,39]
High Treg percentage [38]
MDSCs
Low baseline MDSC numbers [23,44–47]
Decreased MDSC numbers after ICI therapy [38,48,49]
Monocytes Increased baseline frequency of classical CD14+CD16- monocytes [17]
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Abbreviations
ALC absolute lymphocyte count
ANC absolute neutrophil count
APC antigen-presenting cell
CTL cytotoxic T lymphocyte
HPD hyperprogressive disease.
ICI immune checkpoint inhibitors
MDSC myeloid-derived suppressor cell
NLR neutrophil-to-lymphocyte ratio
NSCLC non-small cell lung cancer
ORR overall response rate
OS overall survival
PBMCs peripheral blood mononuclear cells
PFS progression-free survival
RCC renal cell carcinoma
TAM tumor-associated macrophage
TMB tumor mutational burden
TME tumor microenvironment
Treg regulatory T cell
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